Therefore, based on our findings and the frequent presence of ATRX mutations in patients who suffer secondary GBM or anaplastic astrocytomas, we suggest that the analyses of these clinical trials data should consider the ATRX status. This evidence concerns the gene ATRX and anaplastic astrocytoma.